Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Abstract 6024: A novel carbonic anhydrase IX targeting radiopeptide, ⁶⁴Cu-PD-32766 and ¹⁷⁷Lu-PD-32766, exhibit promising theranostic potential in ccRCC tumors

Yoshihide Mizukoshi, Shota Tsuchida, Hiroko Inaba, Tatsuro Kotake, Takanori Aoki, Kai Orihara, Yuichi Funase, Naoki Kanazawa, Hikaru Shimizu, Kaita Sawano, Kentaro Suzuki, Hayato Yanagida, Takeru Ehara, Hidetomo Kitamura, Satoshi Matsushima, Masato Murakami

Cancer Res (2024) 84 (6_Supplement): 6024.

https://doi.org/10.1158/1538-7445.AM2024-6024

Published: 22 March 2024

View article titled, Abstract 6024: A novel carbonic anhydrase IX targeting radiopeptide, 64Cu-PD-32766 and 177Lu-PD-32766, exhibit promising theranostic potential in ccRCC tumors

Journal Articles

Abstract 5880: Pan-cancer gene expression analysis of tissue microarray using EdgeSeq Oncology Biomarker Panel and a cross-comparison with ERBB3 immunohistochemical analysis

Koichiro Inaki, Naoyuki Maeda, Tomoko Shibutani, Serenella Eppenberger-Castori, Stefan Nicolet, Kumiko Koyama, Yui Tanaka, Yuki Kaneda, Kenichi Wakita, Yoshinobu Shiose, Masato Murakami

Cancer Res (2020) 80 (16_Supplement): 5880.

https://doi.org/10.1158/1538-7445.AM2020-5880

Published: 15 August 2020

View article titled, Abstract 5880: Pan-cancer gene expression analysis of tissue microarray using EdgeSeq Oncology Biomarker Panel and a cross-comparison with ERBB3 immunohistochemical analysis

Journal Articles

Abstract 5201: U3-1402, a novel HER3-targeting antibody-drug conjugate, exhibits in vitro antitumor activity against breast cancer cells expressing HER3 mutations without dependence on HER2 overexpression

Kumiko Koyama, Hirokazu Ishikawa, Manabu Abe, Yoshinobu Shiose, Suguru Ueno, Kenji Nakamaru, Masato Murakami

Cancer Res (2020) 80 (16_Supplement): 5201.

https://doi.org/10.1158/1538-7445.AM2020-5201

Published: 15 August 2020

View article titled, Abstract 5201: U3-1402, a novel HER3-targeting antibody-drug conjugate, exhibits in vitro antitumor activity against breast cancer cells expressing HER3 mutations without dependence on HER2 overexpression

Journal Articles

Abstract LB-264: Autophagy modulates intracellular dynamics of [fam-] trastuzumab deruxtecan (DS-8201a), a novel HER2 antibody-drug conjugate (HER2-ADC)

Manabu Abe, Motoko Nagata, Kumiko Koyama, Satoru Yasuda, Tsuyoshi Hirata, Yusuke Kuwahara, Koichiro Inaki, Naomi Kasanuki, Megumi Minami, Katsunobu Hagihara, Kenichi Wakita, Eric Slosberg, Masato Murakami

Cancer Res (2019) 79 (13_Supplement): LB-264.

https://doi.org/10.1158/1538-7445.AM2019-LB-264

Published: 01 July 2019

View article titled, Abstract LB-264: Autophagy modulates intracellular dynamics of [fam-] trastuzumab deruxtecan (DS-8201a), a novel HER2 antibody-drug conjugate (HER2-ADC)

Journal Articles

Abstract LB-275: U3-1402, a novel HER3-targeting antibody-drug conjugate, exhibits its antitumor activity through increased payload intracellular delivery via highly efficient drug internalization

Kumiko Koyama, Yuuri Hashimoto, Yasuki Kamai, Yoshinobu Shiose, Manabu Abe, Yuki Kaneda, Naoyuki Maeda, Kenji Hirotani, Yusuke Ogitani, Tsuyoshi Karibe, Takashi Kagari, Kenichi Wakita, Suguru Ueno, Toshinori Agatsuma, Masato Murakami

Cancer Res (2019) 79 (13_Supplement): LB-275.

https://doi.org/10.1158/1538-7445.AM2019-LB-275

Published: 01 July 2019

View article titled, Abstract LB-275: U3-1402, a novel HER3-targeting antibody-drug conjugate, exhibits its antitumor activity through increased payload intracellular delivery via highly efficient drug internalization

Journal Articles

Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53–MDM2 Inhibitor HDM201

Cancer Res (2018) 78 (21): 6257–6267.

https://doi.org/10.1158/0008-5472.CAN-18-0338

Published: 01 November 2018

View article titled, Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53–MDM2 Inhibitor HDM201

Includes: Supplementary data

Journal Articles

Abstract 2098: NVP-FGF401, a first-in-class highly selective and potent FGFR4 inhibitor for the treatment of HCC

Diana Graus Porta, Andreas Weiss, Robin A. Fairhurst, Markus Wartmann, Christelle Stamm, Flavia Reimann, Alexandra Buhles, Jaqueline Kinyamu-Akunda, Dario Sterker, Masato Murakami, Youzhen Wang, Jeffrey Engelman, Francesco Hofmann, William R. Sellers

Cancer Res (2017) 77 (13_Supplement): 2098.

https://doi.org/10.1158/1538-7445.AM2017-2098

Published: 01 July 2017

View article titled, Abstract 2098: NVP-FGF401, a first-in-class highly selective and potent FGFR4 inhibitor for the treatment of HCC

Journal Articles

Abstract 2103: NVP-FGF401: Cellular and in vivo profile of a novel highly potent and selective FGFR4 inhibitor for the treatment of FGF19/FGFR4/KLB+ tumors

Andreas Weiss, Diana Graus Porta, Flavia Reimann, Alexandra Buhles, Christelle Stamm, Robin A. Fairhurst, Jacqueline Kinyamu-Akunda, Dario Sterker, Masato Murakami, Markus Wartmann, Youzhen Wang, Jeffrey A. Engelman, Francesco Hofmann, Wiliam R. Sellers

Cancer Res (2017) 77 (13_Supplement): 2103.

https://doi.org/10.1158/1538-7445.AM2017-2103

Published: 01 July 2017

View article titled, Abstract 2103: NVP-FGF401: Cellular and in vivo profile of a novel highly potent and selective FGFR4 inhibitor for the treatment of FGF19/FGFR4/KLB+ tumors

Journal Articles

Abstract 2343: The immune modulatory roles of IAP inhibitor, LCL161, and its connection to immune-checkpoint molecules

Maria Pinzon-Ortiz, William Hastings, Tyler Longmire, Pamela Shaw, Xianhui Rong, Masato Murakami, Benjamin H. Lee, Glenn Dranoff, Kenzie MacIsaac, Z. Alexander Cao

Cancer Res (2016) 76 (14_Supplement): 2343.

https://doi.org/10.1158/1538-7445.AM2016-2343

Published: 15 July 2016

View article titled, Abstract 2343: The immune modulatory roles of IAP inhibitor, LCL161, and its connection to immune-checkpoint molecules

Journal Articles

Abstract 1314: Evaluation of PD-L1 mRNA and protein expression in non-small cell lung and hepatocellular carcinoma

Savina Jaeger, Benjamin H. Lee, Rebecca Mosher, Olga Shebnova, Yan Wang, Yenyen Yu, David Yang, Masato Murakami, Joel Greshock, Robert Schlegel, Anthony Boral, Zhu Alexander Cao

Cancer Res (2015) 75 (15_Supplement): 1314.

https://doi.org/10.1158/1538-7445.AM2015-1314

Published: 01 August 2015

View article titled, Abstract 1314: Evaluation of PD-L1 mRNA and protein expression in non-small cell lung and hepatocellular carcinoma

Journal Articles

Abstract 1797: Discovery of NVP-CGM097, a highly potent and optimized small molecule inhibitor of Mdm2 under evaluation in a Phase I clinical trial

Cancer Res (2014) 74 (19_Supplement): 1797.

https://doi.org/10.1158/1538-7445.AM2014-1797

Published: 01 October 2014

View article titled, Abstract 1797: Discovery of NVP-CGM097, a highly potent and optimized small molecule inhibitor of Mdm2 under evaluation in a Phase I clinical trial

Journal Articles

Abstract 2909: A gene signature composed of 13 p53 target genes predicts for response to NVP-CGM097, a novel p53-Mdm2 inhibitor, in cell lines and in human primary tumor xenograft models

Sebastien Jeay, Swann Gaulis, Stéphane Ferretti, Geneviève Albrecht, Louise Barys, Daniel Guthy, Ensar Halilovic, Moriko Ito, Masato Murakami, Astrid Pornon, Stephan Ruetz, Kavitha Venkatesan, Jianjun Yu, Michael Jensen, Marion Wiesmann, Jens Wuerthner, Diana Graus-Porta

Cancer Res (2014) 74 (19_Supplement): 2909.

https://doi.org/10.1158/1538-7445.AM2014-2909

Published: 01 October 2014

View article titled, Abstract 2909: A gene signature composed of 13 p53 target genes predicts for response to NVP-CGM097, a novel p53-Mdm2 inhibitor, in cell lines and in human primary tumor xenograft models

Journal Articles

Abstract LB-36: JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: A rationale for co-targeting these pathways in metastatic breast cancer.

Adrian Britschgi, Rita Andraos, Heike Brinkhaus, Inna Klebba, Masato Murakami, Vincent Romanet, Urs Müller, Thomas Radimerski, Mohamed Bentires-Alj

Cancer Res (2013) 73 (8_Supplement): LB-36.

https://doi.org/10.1158/1538-7445.AM2013-LB-36

Published: 15 April 2013

View article titled, Abstract LB-36: JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: A rationale for co-targeting these pathways in metastatic breast cancer.

Journal Articles

Inactivation of Junctional Adhesion Molecule-A Enhances Antitumoral Immune Response by Promoting Dendritic Cell and T Lymphocyte Infiltration

Masato Murakami, Chiara Francavilla, Ilaria Torselli, Monica Corada, Luigi Maddaluno, Antonio Sica, Gianluca Matteoli, Iliyan Dimitrov Iliev, Alberto Mantovani, Maria Rescigno, Ugo Cavallaro, Elisabetta Dejana

Cancer Res (2010) 70 (5): 1759–1765.

https://doi.org/10.1158/0008-5472.CAN-09-1703

Published: 28 February 2010

View article titled, Inactivation of Junctional Adhesion Molecule-A Enhances Antitumoral Immune Response by Promoting Dendritic Cell and T Lymphocyte Infiltration

Includes: Supplementary data

NARROW

Abstract 6024: A novel carbonic anhydrase IX targeting radiopeptide, ⁶⁴Cu-PD-32766 and ¹⁷⁷Lu-PD-32766, exhibit promising theranostic potential in ccRCC tumors

Abstract 5880: Pan-cancer gene expression analysis of tissue microarray using EdgeSeq Oncology Biomarker Panel and a cross-comparison with ERBB3 immunohistochemical analysis

Abstract 5201: U3-1402, a novel HER3-targeting antibody-drug conjugate, exhibits in vitro antitumor activity against breast cancer cells expressing HER3 mutations without dependence on HER2 overexpression

Abstract LB-264: Autophagy modulates intracellular dynamics of [fam-] trastuzumab deruxtecan (DS-8201a), a novel HER2 antibody-drug conjugate (HER2-ADC)

Abstract LB-275: U3-1402, a novel HER3-targeting antibody-drug conjugate, exhibits its antitumor activity through increased payload intracellular delivery via highly efficient drug internalization

Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53–MDM2 Inhibitor HDM201

Abstract 2098: NVP-FGF401, a first-in-class highly selective and potent FGFR4 inhibitor for the treatment of HCC

Abstract 2103: NVP-FGF401: Cellular and in vivo profile of a novel highly potent and selective FGFR4 inhibitor for the treatment of FGF19/FGFR4/KLB+ tumors

Abstract 2343: The immune modulatory roles of IAP inhibitor, LCL161, and its connection to immune-checkpoint molecules

Abstract 1314: Evaluation of PD-L1 mRNA and protein expression in non-small cell lung and hepatocellular carcinoma

Abstract 1797: Discovery of NVP-CGM097, a highly potent and optimized small molecule inhibitor of Mdm2 under evaluation in a Phase I clinical trial

Abstract 2909: A gene signature composed of 13 p53 target genes predicts for response to NVP-CGM097, a novel p53-Mdm2 inhibitor, in cell lines and in human primary tumor xenograft models

Abstract LB-36: JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: A rationale for co-targeting these pathways in metastatic breast cancer.

Inactivation of Junctional Adhesion Molecule-A Enhances Antitumoral Immune Response by Promoting Dendritic Cell and T Lymphocyte Infiltration

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only